Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer

被引：0
|
作者：
Tran, Phuong T. [1 ,2 ]
Diaby, Vakaramoko [1 ]
机构：
[1] Univ Florida, Coll Pharm, Gainesville, FL 32611 USA
[2] Ho Chi Minh City Univ Technol HUTECH, Fac Pharm, Ho Chi Minh City, Vietnam
来源：
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2020年 / 26卷 / 02期
关键词：
D O I：
10.18553/jmcp.2020.26.2.221
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：221 / 221
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of Adjuvant Neratinib Following Trastuzumab in Early-Stage HER2-Positive Breast Cancer
    Schwartz, Naomi R. M.
    Flanagan, Meghan R.
    Babigumira, Joseph B.
    Steuten, Lotte M.
    Roth, Joshua A.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (10): : 1133 - 1139
  • [2] POTENTIAL COST-EFFECTIVENESS OF NERATINIB FOLLOWING TRASTUZUMAB THERAPY FOR TREATMENT OF EARLY-STAGE HER2-POSITIVE BREAST CANCER
    Schwartz, N. R.
    Steuten, L.
    Babigumira, J. B.
    Roth, J. A.
    [J]. VALUE IN HEALTH, 2018, 21 : S28 - S28
  • [3] Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective?
    Schwartz, Naomi R. M.
    Flanagan, Meghan Rose
    Babigumira, Joseph B.
    Steuten, Lotte Maria Gertruda
    Roth, Joshua A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Cost-effectiveness analysis (CEA) of adjuvant trastuzumab therapy use in HER2-positive early-stage breast cancer (EBC)
    Quintyne, K. I.
    Woulfe, B.
    Dee, A.
    Gupta, R.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer
    Hajjar, Ali
    Ergun, Mehmet A.
    Alagoz, Oguzhan
    Rampurwala, Murtuza
    [J]. PLOS ONE, 2019, 14 (06):
  • [6] Neratinib in Early-Stage HER2-Positive Breast Cancer
    Cherian, Mathew A.
    Ma, Cynthia X.
    [J]. BREAST DISEASES, 2015, 26 (04): : 285 - 287
  • [7] COST-EFFECTIVENESS ANA LYSIS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY OF EARLY-STAGE HER2-POSITIVE BREAST CANCER
    Nguyen, T. T. C.
    Nguyen, T. T. T.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A735 - A735
  • [8] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
    Garrison, Louis R., Jr.
    Lubeck, Deborah
    Lalla, Deepa
    Paton, Virginia
    Dueck, Amylou
    Perez, Edith A.
    [J]. CANCER, 2007, 110 (03) : 489 - 498
  • [9] Cost-effectiveness analysis of adjuvant therapy with trastuzumab for HER2-positive early breast cancer in polish setting
    Orlewska, E.
    Pienkowski, T.
    Drosik, K.
    Gyldmark, M.
    Aultman, R.
    Szkultecka-Debek, M.
    [J]. VALUE IN HEALTH, 2007, 10 (03) : A125 - A125
  • [10] COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER
    Nguyen, T. T. T.
    Yagudina, R.
    Kulikov, A. U.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A165 - A165
12345